[Review of the indications of stereotactic body radiation therapy (SBRT) in patients with primary tumours and oligometastases]

Maceira-Rozas MC, Salvador Garrido N
Record ID 32014000352
Spanish
Original Title: Revisión de las indicaciones de la radioterapia estereotáxica corporal (SBRT) en pacientes con tumores primarios y oligometástasis
Authors' objectives: To undertake a systematic review of the literature containing published reports of treatment with stereotactic body radiation therapy (SBRT), and provide a general overview of SBRT's current status in terms of efficacy, safety and cost-effectiveness.
Authors' recommendations: SBRT would appear to be widely used for treatment of a variety of types of cancer. Comparative studies are needed to provide evidence to show that the theoretical advantages of SBRT versus other treatments are to be seen in the clinical setting. Currently, the use of SBRT can only be recommended in stage I non-small-cell lung tumours, among patients with contraindication of surgery and isolated pulmonary oligometastasis. For the remaining sites, this technique can only be recommended in protocols of clinical trials or in those cases where there is no other alternative that has shown greater clinical efficacy.
Details
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Radiotherapy
  • Radiotherapy Planning, Computer-Assisted
  • Radiosurgery
  • Neoplasm Metastasis
  • Neoplasms
Contact
Organisation Name: Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
Contact Address: Conselleria de Sanidade, Xunta de Galicia, San Lazaro s/n 15781 Santiago de Compostela, Spain. Tel: 34 981 541831; Fax: 34 981 542854;
Contact Name: avalia-t@sergas.es
Contact Email: avalia-t@sergas.es
Copyright: Galician Agency for Health Technology Assessment (AVALIA-T)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.